Novoprotein Scientific Inc. (SHA:688137)
122.84
-1.66 (-1.33%)
At close: Sep 23, 2026
Novoprotein Scientific Revenue
Novoprotein Scientific had revenue of 41.25M CNY in the quarter ending June 30, 2026, with 6.73% growth. This brings the company's revenue in the last twelve months to 152.84M, up 9.18% year-over-year. In the year 2025, Novoprotein Scientific had annual revenue of 146.44M with 14.80% growth.
Revenue (ttm)
152.84M
Revenue Growth
+9.18%
P/S Ratio
55.87
Revenue / Employee
219.60K
Employees
696
Market Cap
8.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.44M | 18.88M | 14.80% |
| Dec 31, 2024 | 127.56M | -25.64M | -16.73% |
| Dec 31, 2023 | 153.19M | -111.36M | -42.09% |
| Dec 31, 2022 | 264.55M | -77.34M | -22.62% |
| Dec 31, 2021 | 341.90M | 162.05M | 90.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.93B |
| Novogene | 2.28B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.69B |
| Chengdu Kanghua Biological Products | 1.22B |
| R&G PharmaStudies | 939.31M |
| Zhejiang Ausun Pharmaceutical | 778.50M |
| Daan Gene | 746.91M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |